Changing the Course of Cancer Care
By 2026, approximately 20 million people in the U.S. will be living with
cancer. As the needs of surviving cancer patients evolve worldwide, TYME
remains dedicated to advancing its pipeline of proprietary Cancer
Metabolism-Based Therapies (CMBTs™) for difficult-to-treat cancers.
Our focus is to advance our research to reach patients in need around
the world who experience advanced metastatic cancers and
life-threatening rare diseases.
CMBTs are investigational proprietary compounds that are hypothesized to disrupt the protein synthesis of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that our lead oral candidate, SM-88, has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate, sarcoma and lymphoma cancers with minimal Grade 3 or higher serious adverse events.
Clinical trials are essential to our research and development work, through which we want to ensure that our medicines are better and safer. We strive to give cancer patients with limited treatment options hope for a longer, better life.
Why Participate?
Patients enroll in clinical trials for many reasons. These often include interest in advancing science and medical care, interest in gaining access to new, experimental treatments – especially if all other treatment options have failed – and also, interest in learning more about their medical condition. Some patients may benefit from participating in a clinical trial if the investigational drug turns out to be effective, but there is no guarantee that a volunteer will receive any direct benefit.
By volunteering to participate in clinical trials, participants help advance what we know about medical interventions. In doing so, clinical trial participants can play an important role in getting new drugs and devices approved for use in treating other patients.